With 90 years of know-how, we are a global leader in the probiotic industry, specializing in the development, production, and marketing of bacteria- and yeast-based probiotic supplements for human health, nutricosmetics and food applications. Our production facilities meet the highest quality standards, including Good Manufacturing Practices, and we maintain a robust research program through the Rosell Institute for Microbiome and Probiotics. We offer our partners clinically documented probiotic strains for a wide range of health applications, including gut health, immune support, mental well-being, women’s health, skin and oral health, sports, metabolic health, healthy aging, and infant health. Today, we offer more than 600 probiotic formulas across over 60 countries.
Our research, led by the Rosell Institute for Microbiome and Probiotics, supports a diverse portfolio of proprietary probiotic strains. Our team is at the forefront of innovation, with over 430 publications, more than 160 completed clinical trials, 100+ in vitro and 80+ in vivo studies, and the management of 20+ ongoing clinical trials across four continents.
We maintain a strong focus on robust pre-clinical and clinical research programs, while forging strategic partnerships along the way. We do not just talk about innovation, we deliver it. And with a strong pipeline of innovations ahead, we remain committed to supporting our partners in achieving success in their markets.
At Lallemand Health Solutions, we turn vision into action. Here is an overview of some of the innovations we have presented in the running year, illustrating how we have truly walked the talk, leading the way in probiotic innovation.
2025 Innovation Highlights
Launch of Cerenity™ for healthy aging
Lallemand Health Solutions launched a complete offer for Healthy Aging, led by Cerenity™, a clinically documented formula to supports mobility, strength, and quality of life in healthy aging. Cerenity™ is a powerful blend of three flagship probiotic strains, designed to modulate the gut-muscle axis, for healthy aging from within. A 16-week clinical trial showed significant improvements in physical performance and muscle strength, reinforcing the role of gut health in aging well.
Women’s Health: New Research Results
Year after year, important R&D efforts are invested to bring forward innovative health solutions for women. Discover the results of a new clinical study exploring the benefits of probiotics on healthy women during the menstrual cycle. We also launched Prenatis® to maintain a healthy pregnancy and to contribute to the establishment of a healthy infant microbiome during the first months of life.
Cerebiome®: Demonstrates Benefits on Overall Wellbeing, Including Sleep
A pioneer in gut-brain axis research, Lallemand Health Solutions has new findings on Cerebiome®, its flagship psychobiotic. We have gathered compelling evidence showing Cerebiome®’s benefits on overall wellbeing, including sleep quality and skin appearance. A proof-of-concept study revealed improvements in perceived stress, circadian rhythm, and holistic beauty, reinforcing Cerebiome®’s potential beyond occasional stress.
Award-Winning Postbiotic IMMUSE® for Immune Health
Earlier this year, Lallemand Health Solutions and Kirin Holdings Company, Limited announced a strategic partnership to expand the visibility of IMMUSE®, a clinically researched lactic acid bacteria developed by Kirin Holdings Company, Limited. IMMUSE® is a heat-inactivated Lactococcus lactis strain Plasma, backed by 15 clinical trials demonstrating its efficacy in supporting immune health through a distinctive mode of action.
Contact LHS: healthsolutions@lallemand.com
Visit our website for more information
Follow LHS on LinkedIn
